Globus Medical Releases FY 2026 Earnings Guidance

Got story updates? Submit your updates here. ›

Globus Medical (NYSE:GMED), a leading manufacturer of musculoskeletal solutions for spine and orthopedic applications, has issued its earnings guidance for the fiscal year 2026. The company expects to report earnings per share (EPS) in the range of $4.40 to $4.50, exceeding the current consensus estimate of $4.07. Globus Medical also provided revenue guidance of $3.2 billion, above the consensus estimate of $3.1 billion.

Why it matters

Globus Medical's strong financial guidance reflects the company's continued growth and success in the medical device market. As a leading provider of innovative spine and orthopedic solutions, the company's performance is closely watched by investors and industry analysts. The positive outlook suggests Globus Medical is well-positioned to capitalize on ongoing trends in the healthcare sector, such as the increasing demand for minimally invasive surgical procedures and the adoption of advanced technologies like robotics and navigation systems.

The details

Globus Medical's earnings guidance for fiscal year 2026 represents a significant increase from the company's previous performance. In the most recent quarter, Globus Medical reported EPS of $1.28, exceeding the consensus estimate of $1.06, and revenue of $826.42 million, up 25.7% year-over-year. The company's strong financial results have been driven by the continued success of its core spine business, as well as its expansion into adjacent markets like robotics and navigation systems.

• Globus Medical issued its FY 2026 earnings guidance on Friday, February 27, 2026.
• The company's most recent quarterly earnings report was released on Tuesday, February 24, 2026.

What’s next

Globus Medical's earnings guidance for FY 2026 will be a key focus for investors and analysts in the coming months, as they assess the company's long-term growth prospects and competitive positioning in the medical device industry.